In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy

被引：0
作者：
Aleksandra Syguła
Aleksandra Ledwon
Kornelia Hasse-Lazar
Beata Jurecka-Lubieniecka
Barbara Michalik
Ewa Paliczka-Cieślik
Marcin Zeman
Ewa Chmielik
Joanna Sczasny
Barbara Jarzab
Daria Handkiewicz-Junak
机构：
[1] Maria Sklodowska-Curie National Research Institute of Oncology,Department of Nuclear Medicine and Endocrine Oncology, Gliwice Branch
[2] Maria Sklodowska-Curie National Research Institute of Oncology,The Oncologic and Reconstructive Surgery Clinic, Gliwice Branch
[3] Maria Sklodowska-Curie National Research Institute of Oncology,Tumor Pathology Department, Gliwice Branch
[4] Maria Sklodowska-Curie National Research Institute of Oncology,Radiology and Diagnostic Imaging Department, Gliwice Branch
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2022年 / 49卷
关键词：
Neuroendocrine malignancies; Peptide receptor radionuclide therapy; Somatostatin analogues; Sequential treatment; Survival;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3841 / 3851
页数：10
相关论文
共 239 条
[61]  
Handkiewicz Junak D(undefined)undefined undefined undefined undefined-undefined
[62]  
Rocca P(undefined)undefined undefined undefined undefined-undefined
[63]  
Papi S(undefined)undefined undefined undefined undefined-undefined
[64]  
Lopera Sierra M(undefined)undefined undefined undefined undefined-undefined
[65]  
Strosberg J(undefined)undefined undefined undefined undefined-undefined
[66]  
El-Haddad G(undefined)undefined undefined undefined undefined-undefined
[67]  
Wolin E(undefined)undefined undefined undefined undefined-undefined
[68]  
Hendifar A(undefined)undefined undefined undefined undefined-undefined
[69]  
Yao J(undefined)undefined undefined undefined undefined-undefined
[70]  
Chasen B(undefined)undefined undefined undefined undefined-undefined
234567891011